GlassScriptPhysician profile
Tonnetta Quigley
NPI 1043644131
$3,108.13
in general payments reported to CMS, 2019-2025
47 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $258 · 2021: $111 · 2022: $250 · 2023: $360 · 2024: $494 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $366.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $273.64 | 2019-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $188.27 | 2019-2023 | Trintellix |
| Abbvie INC. | $179.17 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.00 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Pfizer INC. | $95.03 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $92.54 | 2019-2024 | |
| Dexcom, INC. | $78.98 | 2022-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $71.72 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $67.33 | 2019-2020 | |
| Corcept Therapeutics | $66.76 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $64.21 | 2019-2024 | Belsomra, Segluromet, Steglujan |
| Glaxosmithkline, LLC. | $61.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.28 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonnetta Quigley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.